Figure 3.

Consumption of carbapenems in the hospital sector and carbapenems resistance in Klebsiella pneumoniae, including detected trend segments, EU/EEA population-weighted means, 2001–2018

DDD: defined daily doses; EU/EEA: European Union and European Economic Area.

^a Carbapenem resistance in E. coli was not included. Because carbapenem resistance is rare in E. coli isolates in the EU/EEA, carbapenem susceptibility is in many cases not routinely determined for this species in clinical microbiology laboratories.

Antimicrobial consumption trend segments are shown in red. AMR trend segments are shown in blue.